News
ADMS
8.22
+0.74%
0.06
BRIEF-Supernus Pharma Announces Expiration Of Hart-Scott-Rodino Waiting Period For Adamas Pharma Tender Offer
reuters.com · 11/23/2021 13:35
Northland Capital Markets Downgrades Adamas Pharmaceuticals to Market Perform, Announces $8.5 Price Target
Northland Capital Markets analyst Carl Byrnes downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Outperform to Market Perform and announces $8.5 price target.
Benzinga · 11/17/2021 12:41
Adamis Pharmaceuticals Shares Move Higher; Traders Circulate Event Page For VirginiaBio. BZ NOTE: Co To Present Wednesday, Nov. 17
https://www.vabio.org/event/use-of-tempol-as-an-antiviral-therapeutic-against-covid-19/
Benzinga · 11/16/2021 19:33
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire · 11/09/2021 18:12
Supernus up 10% following 2021 earnings guidance boost, Q3 beat
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) are up ~10% in after-hours trading after the company boosted its full-year earnings guidance and beat Q3 earnings estimates. Operating earnings for 2021 are now expected to
Seekingalpha · 11/03/2021 22:01
How Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?
If you want to know who really controls Adamas Pharmaceuticals, Inc. ( NASDAQ:ADMS ), then you'll have to look at the...
Simply Wall St. · 11/02/2021 10:26
Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know
Zacks.com · 10/28/2021 04:41
Adamas Pharmaceuticals Shares Move Higher; Magnetar Financial Reports In 13D Filing A 6.85% Stake In Co
-SEC Filing
SEC Filing · 10/19/2021 20:29
Rockville biotech banks on new revenue with $450M acquisition of a West Coast drugmaker
The deal creates some immediate and long-term opportunities for Supernus, which focuses on central nervous system diseases.
American City Business Journals · 10/15/2021 18:33
10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly t...
Insider Monkey · 10/14/2021 10:57
APRN, CEI and GOTU among mid-day movers
Gainers: Protagonist (NASDAQ:PTGX) +86%. Adamas (NASDAQ:ADMS) +75%. Flexion (NASDAQ:FLXN) +63%. Progenity (NASDAQ:PROG) +35%. Gaotu Techedu (NYSE:GOTU) +23%. U.S. Well Services (NASDAQ:USWS) +22%. Blue Apron (NYSE:APRN) +19%. EZFill (NASDAQ:EZFL) +18%. Ocu...
Seekingalpha · 10/11/2021 16:39
Supernus bolsters Parkinson's portfolio with $400 million deal for Adamas Pharma
Supernus Pharmaceuticals Inc said on Monday it would buy Adamas Pharmaceuticals Inc for about $400 million, to expand its roster of treatments for Parkinson's disease and reduce reliance on its top-selling epilepsy medicine.
Reuters · 10/11/2021 16:10
28 Stocks Moving In Monday's Mid-Day Session
Gainers
Benzinga · 10/11/2021 16:04
William Blair Downgrades Adamas Pharmaceuticals to Market Perform
William Blair analyst Tim Lugo downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Outperform to Market Perform.
Benzinga · 10/11/2021 15:44
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
Benzinga · 10/11/2021 12:53
CAPR, CPG and AVDL among pre market gainers
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NAS...
Seekingalpha · 10/11/2021 12:21
BRIEF-Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
reuters.com · 10/11/2021 12:02
UPDATE 2-Supernus bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma
reuters.com · 10/11/2021 11:25
Adamas Announces New Employment Inducement Grants
EMERYVILLE, Calif., October 08, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the compan...
Business Wire · 10/08/2021 20:15
BRIEF-Cognoa Appoints Tony Rimac As Chief Financial Officer
reuters.com · 09/30/2021 14:25
More
Webull provides a variety of real-time ADMS stock news. You can receive the latest news about Adamas Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ADMS
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.